Insulin Resistance and Intramyocellular Lipid Content in Glucose Intolerant Subjects Receiving Rosiglitazone

Phase 4 Completed 24 enrolled University of Texas Southwestern Medical Center GlaxoSmithKline · collab

RandomizedCrossoverQuadruple-blindTreatment

Summary

This study will include subjects with an abnormal glucose tolerance test. Using a crossover design, we will evaluate the insulin sensitivity and intracellular lipid content of the heart, liver and skeletal muscle of subjects before and after therapy with Rosiglitazone and placebo. We hypothesize that Rosiglitazone will improve insulin sensitivity in association with reduced muscle lipid content that may arise either from increased lipid oxidation or enhanced storage of fat in adipose tissue.

Timeline

Start: 2004-02
Primary completion: 2007-03
Completion: 2008-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Rosiglitazone	Small molecule	8 mg	Oral

Indications

No indication recorded.